Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database.
Ontology highlight
ABSTRACT: Background and purpose: Testosterone is an essential sex hormone in maintaining masculine characteristics, which is prescribed for male hypogonadism as testosterone replacement treatment (TRT). Herein, we investigated long-standing controversies about the association between TRT and major adverse cardiovascular events (MACEs), based on real world adverse event (AE) reports, registered in the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Publicly available FAERS data from 1 January 2004 to 31 December 2022 were retrieved from the Food and Drug Administration (FDA) website. The data mining protocol including the reporting odds ratio (ROR) and the Bayesian confidence propagation neural network (BCPNN) was applied to analyze overreporting caused by
SUBMITTER: Zhao H
PROVIDER: S-EPMC10370495 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature
ACCESS DATA